跳到正文
原文
BioPharma Dive· Delilah Alvarado·· 2026-10-13精选AI 评分62

First Tracks 乳糜泻候选药 ANB033 早期试验多项指标较安慰剂显著改善,股价涨约 7%

First Tracks climbs on ‘impressive’ celiac study data

AI 导读

First Tracks Biotherapeutics 公布 ANB033 治疗乳糜泻的早期临床数据,三项研究指标较安慰剂显著改善,公司称无治疗相关严重不良事件。试验纳入 32 名患者,随机接受安慰剂或三剂皮下给药,随后完成两周麸质挑战。公司计划 2027 年启动晚期试验,消息公布当日股价上涨约 7%。

推荐理由

乳糜泻目前没有获批药物,ANB033 的早期数据给出了保护肠黏膜、应对麸质挑战的量化指标,可作为同类 CD122 在研药物的对照参考。

正文 · 原文

An article from site logo

Dive Brief

The company reported positive early-stage data for its celiac drug that has been deemed to have “pipeline-in-a-product potential” by analysts.

Published Oct. 12, 2026

Delilah Alvarado's headshot

An illustration of stock market quotes.

Getty Images

Dive Brief:

  • An experimental drug from First Tracks Biotherapeutics helped reduce signs and symptoms of celiac disease in an early-stage trial. 
  • When compared to a placebo after six weeks of treatment, First Tracks’ drug ANB033 produced a statistically significant improvement on a measure evaluating how well a therapy protects the intestinal lining from gluten-induced damage. The drug hit its marks on other evaluations of disease severity, and also prevented an increase in symptoms during a “gluten challenge,” First Tracks said.
  • There were no serious adverse events related to treatment, nor were there any side effects that led drug recipients to leave the trial. First Tracks will report data from a second study cohort in the first quarter of next year, and expects to start a late-stage trial in 2027 as well. 

Dive Insight:

Celiac disease is an immune disorder in which consuming gluten causes the body to mistakenly attack the small intestine. Over time, the damage disrupts the absorption of vitamins and minerals, triggering deficiencies and digestive symptoms. While a strict diet can help sidestep these issues, some drugmakers are hoping an emerging, targeted kind of medication could provide a different option. 

First Tracks, Argenx and Teva Pharmaceuticals all have drug prospects in clinical testing against celiac. First Tracks’ drug ANB033 blocks the activity of CD122, a receptor component used by two immune-regulating proteins IL-2 and IL-15. Argenx’s therapy, acquired in a recent buyout, also targets CD122. Teva’s treatment homes in on IL-15 specifically.  

Teva and Argenx’s drugs have already shown promise in early celiac trials. Their success heightened anticipation for the findings First Tracks reported on Monday. 

First Tracks enrolled 32 participants and randomized them to receive a placebo or three subcutaneously administered doses of ANB033 over the course of four weeks. Participants then underwent a two-week gluten challenge, which was the equivalent of eating about two slices of bread each day.

ANB033 hit statistical significance on three different study measures assessing biological signs of celiac. Those findings, as well as “clean safety,” make for “impressive” initial results, wrote Leerink Partners analyst David Risinger in a Monday client note. 

Though the two drugs haven’t been formally tested against one another, First Tracks’ data compares “favorably” to the results Teva disclosed last month, Risinger wrote. 

“We view ANB033 as having pipeline-in-a-product potential across several autoimmune diseases,” he added.

The drug is also being tested in a Phase 1b trial in eosinophilic esophagitis, with data expected in the third quarter of 2027. First Tracks said it is also on track to start Phase 2 development in the skin disease vitiligo, as well as another unnamed indication, in the first half of 2027.

“Celiac disease is the largest autoimmune disease without an approved treatment,” Monique da Silva, First Tracks’ senior vice president of corporate affairs, told BioPharma Dive.

Should the early results be confirmed in further testing, the drug could offer people with the condition a “new layer of protection beyond the gluten-free diet,” she added. 

Company shares climbed about 7% in Monday trading.

来源:BioPharma Dive · biopharmadive.com